Glucovance

Glucovance is an oral combination medication containing Metformin Hydrochloride and Glibenclamide. It is supplied as a tablet (strength varies by market) and is available in the European Union by prescription only. Classified as a biguanide and sulfonylurea, the product helps lower blood glucose in adults with type 2 diabetes by reducing hepatic glucose production and enhancing insulin release from pancreatic beta cells as part of a comprehensive treatment plan.

Glucovance is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus, typically when diet, exercise, and monotherapy have not achieved target glucose levels.

- As an adjunct to lifestyle modification to improve overall glycemic control. - In combination with other oral antidiabetic agents when additional glucose lowering is required. - For patients who need both decreased hepatic glucose output and increased insulin secretion. - To help achieve individualized HbA1c goals as part of a comprehensive diabetes management plan. - When renal function is stable and the patient does not have contraindications to either component, Glucovance may be considered as a single‑tablet regimen.

The safety profile of Glucovance reflects the combined actions of metformin and glibenclamide, producing a range of adverse events that are reported with varying frequency.

Common: - Gastrointestinal discomfort such as nausea, abdominal pain, or diarrhea. - Mild hypoglycemia, especially when meals are skipped or delayed. - Metallic taste in the mouth. - Weight gain or fluid retention. - Headache or mild dizziness. - Decreased appetite or early satiety.

Serious: - Lactic acidosis, a rare but life‑threatening condition associated with metformin accumulation. - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including skin rash, itching, or swelling of the face and throat. - Pancreatitis presenting with severe abdominal pain.

When prescribing Glucovance, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse outcomes.

- Assess renal function before initiation and periodically thereafter, as impaired clearance can raise metformin levels. - Use caution in patients with hepatic impairment, heart failure, or a history of lactic acidosis. - Avoid use in pregnant women unless the potential benefit outweighs risk; the drug is classified as pregnancy category C. - Monitor blood glucose closely to prevent hypoglycemia, especially when dietary intake changes. - Discontinue or adjust dose before any radiographic procedures that use iodinated contrast agents. - Educate patients on recognizing signs of hypoglycemia and lactic acidosis.

Glucovance may interact with other medicines, altering its effectiveness or increasing the risk of side effects.

Avoid: - Iodinated contrast agents administered intra‑arterially or intravenously, which can precipitate metformin‑associated lactic acidosis. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glibenclamide plasma concentrations. - Other sulfonylureas or meglitinides, which can cause additive hypoglycemia.

Use with caution: - Renal‑impairing drugs such as ACE inhibitors, NSAIDs, or diuretics; monitor kidney function and adjust dose if needed. - Beta‑blockers, which may mask hypoglycemia symptoms. - Alcohol consumption, which can potentiate metformin’s effect on lactate metabolism. - Thyroid hormones, as altered metabolism may affect glucose control.